Exploring the feasibility of early surveillance for type 1 diabetes

  • Research type

    Research Study

  • Full title

    Exploring the acceptability and feasibility of early surveillance for autoimmune diabetes

  • IRAS ID

    294654

  • Contact name

    Parth Narendran

  • Contact email

    p.narendran@bham.ac.uk

  • Sponsor organisation

    University of Birmingham

  • Duration of Study in the UK

    1 years, 8 months, 19 days

  • Research summary

    The ELSA study stage 1 will explore the acceptability of a surveillance programme for early detection of autoimmune type 1 diabetes (T1D).

    Early detection of T1D would identify children who could be invited into future prevention studies (note that prevention studies are not the subject of the ELSA study). Early identification would also avoid T1D being diagnosed in an emergency state, allow earlier treatment to be initiated, and eventually to the reduction in long-term complications. 

    The ELSA study stage 1 is a qualitative study through which we will interview parents and families to understand how acceptable it would be to know their child’s future risk of T1D, and to understand the reasons for and against partaking in a T1D risk stratification and surveillance programme. 
    As part of the ELSA-1 study, we will also be interviewing professional stakeholders, who would be involved in the implementation of a future type 1 diabetes testing and monitoring programme. This will provide us with insights into acceptability and feasibility from a professional stakeholder's perspective.

    Following the interviews, we will hold co-production workshops with parents and professional stakeholders to address and reduce barriers to the implementation of a national type 1 diabetes surveillance programme.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    21/NW/0141

  • Date of REC Opinion

    3 Jun 2021

  • REC opinion

    Further Information Favourable Opinion